Relationship Between Amyloid-β Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background: Preclinical Alzheimer’s disease (AD) is defined by cerebral amyloid-β positivity (Aβ+) in cognitively normal (CN) older adults. Objective: To estimate the risk of progression to the symptomatic stages of AD due to PET Aβ+ and the extent that progression was influenced by other demographic, genetic, and clinical characteristics in a large prospective study. Methods: Fine-Gray subdistribution modeling was used to examine the risk of progression from CN to MCI/dementia due to Aβ+, APOE ɛ4 carriage, and their interaction in the Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of aging CN cohort ( n = 599) over 8 years. Results: 17.7% Aβ+ and 8.1% Aβ–progressed over 8 years (OR: 2.43). Risk of progression for Aβ+ was 65–104% greater than Aβ–. Aβ+ APOE ɛ4 carriers were at 348% greater risk than all other participants. Significant risk factors of progression in Aβ+ were age (HR: 1.05), PET SUVR (HR: 2.49) and APOE ɛ4 carriage (HR: 2.63); only age was a significant risk factor in Aβ–(HR: 1.09). Aβ–progressors were not near the threshold for Aβ+. These relationships were not moderated by hypertension, diabetes, obesity, or stroke/TIA. Conclusion: Aβ+ is an important prognostic marker for progression from CN to MCI/dementia in older adults and APOE ɛ4 carriage provides further predictive value in the presence of Aβ+. These data suggest that Aβ-associated clinical progression is consistent with clinical-pathological models of AD, whereas progression in the absence of elevated Aβ deposition may be the result of neuropathological processes other than AD that accumulate with age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As we noted in the 2017 Commission, others have previously calculated an estimate of the risk associated with APOε4 at 7% taking into account some other risk factors and this estimate highlights how relatively important potentially modifiable risk factors are in dementia.2, 179”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [179]
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139 · cited 1×
“Baseline mood was assessed using the Hospital Anxiety and Depression Scale (HADS) [31], and the Memory Complaint Questionnaire (MAC-Q) [32] was used to assess subjective memory complaint.”
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537 · cited 2×
“…of dementia due to AD, the recent NIA-AA Research Framework proposed that AD be defined by the presence of cortical A (cid:2) and tau aggregates and neurodegeneration rather than by clinical symptoms due to the poor specificity of cognitive symptoms to detect AD neuropathological processes [4].”
Self-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationWinblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Self-citationRisk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Self-citationHuman ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242 · cited 1×
“4 reduces clearance of cerebral A (cid:2) but does not affect rates of A (cid:2) production [39]; therefore, the findings of this study indicate that the impaired clearance of A (cid:2) due to APOE (cid”
Differential aging of the brain: Patterns, cognitive correlates and modifiers
Raz, N., & Rodrigue, K. M. (2006) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2006.07.001 · Cited by 1,195 · cited 1×
“Although A (cid:2) deposition, and therefore risk of disease progression, is known to increase with age [41], other neuropathological processes such as brain atrophy are also associated with age [42].”
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging
Rowe, C. C., Ellis, K. A., Rimajova, M., Bourgeat, P., Pike, K. E., Jones, G., Fripp, J., Tochon-Danguy, H., Morandeau, L., O'Keefe, G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.007 · Cited by 986
Self-citationEllis, K. A., Bush, A. I., Darby, D., De Fazio, D., Foster, J., Hudson, P., Lautenschlager, N. T., Lenzo, N., Martins, R. N., Maruff, P., et al. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009405 · Cited by 968
Self-citationApolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
Roberts, R. O., Geda, Y. E., Knopman, D. S., Cha, R. H., Pankratz, V. S., Boeve, B. F., Ivnik, R. J., Tangalos, E. G., Petersen, R. C., & Rocca, W. A. (2008) · Neuroepidemiology · doi:10.1159/000115751 · Cited by 793 · cited 2×
“Although the prevalence of vascular disease in the population-based MCSA is higher than that found in controlled experimental samples [25], it was reported that adjustment for vascular diseases did not change their progression risk estimates [10].”
InfluentialThe A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J., Donohue, M., Salmon, D. P., & Aisen, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 760 · cited 1×
“Clinical trials of A (cid:2) -lowering drugs have endeavored to recruit CN A (cid:2) + older adults based on their increased risk for incident MCI/dementia in an attempt to slow cognitive decline and prevent onset of symptomatic AD (e.g. Clinical Trials NCT02569398 and NCT02008357) [11].”
Inference by eye: Reading the overlap of independent confidence intervals
Cumming, G. (2009) · Statistics in Medicine · doi:10.1002/sim.3471 · Cited by 670 · cited 1×
“4 carriage and greater A (cid:2) deposition increased risk of progression for the A (cid:2) + group but not for the A (cid:2) – group, and that this difference was significant [36].”
Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study
Vos, S. J., Xiong, C., Visser, P. J., Jasielec, M. S., Hassenstab, J., Grant, E. A., Cairns, N. J., Morris, J. C., Holtzman, D. M., & Fagan, A. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70194-7 · Cited by 564 · cited 1×
“Similarly, estimates of progression at 5 years were based on 25% of the baseline MCSA sample [10], and 35% of the Knight ADRC data were available beyond 5 years [17].”
Self-citationDonohue, M. C., Sperling, R. A., Petersen, R., Sun, C.-K., Weiner, M. W., Aisen, P. S., & Initiative, F. T. A. D. N. (2017) · JAMA · doi:10.1001/jama.2017.6669 · Cited by 452 · cited 4×
“…the Knight Alzheimer’s Disease Research Center study (Knight ADRC, mean age 72) [13], 19% over 6 years in the Australian Imaging, Biomarkers and Lifestyle study (AIBL, mean age 73) [14], to 32.2% over an average of 4 years in the Alzheimer’s Disease Neuroimaging Initiative (ADNI, mean age 74) [15].”
InfluentialAssessment of Memory Complaint in Age-Associated Memory Impairment: The MAC-Q
Crook, T. H., Feher, E. P., & Larrabee, G. J. (1992) · International Psychogeriatrics · doi:10.1017/s1041610292000991 · Cited by 432 · cited 1×
“Baseline mood was assessed using the Hospital Anxiety and Depression Scale (HADS) [31], and the Memory Complaint Questionnaire (MAC-Q) [32] was used to assess subjective memory complaint.”
Chételat, G., La Joie, R., Villain, N., Perrotin, A., de La Sayette, V., Eustache, F., & Vandenberghe, R. (2013) · NeuroImage: Clinical · doi:10.1016/j.nicl.2013.02.006 · Cited by 352 · cited 1×
“Prospective studies in both experimental and epidemiological cohorts have indicated that CN A (cid:2) + adults have higher risk of progression to clinical classification of mild cognitive impairment (MCI) or dementia compared to those without elevated A (cid:2) (i.e., A (cid:2) –) [9, 10].”
Storandt, M., Mintun, M. A., Head, D., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 304
Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Preboske, G. M., Kantarci, K., Raman, M. R., Machulda, M. M., Mielke, M. M., Lowe, V. J., et al. (2015) · Brain · doi:10.1093/brain/awu393 · Cited by 299
Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease
Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A., Huijbers, W., Rentz, D. M., Johnson, K. A., Sperling, R. A., & For the Alzheimer's Disease Neuroimaging Initiative, T. A. I. B. A. L. F. S. O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000431 · Cited by 293
Roberts, R. O., Aakre, J. A., Kremers, W. K., Vassilaki, M., Knopman, D. S., Mielke, M. M., Alhurani, R., Geda, Y. E., Machulda, M. M., Coloma, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0629 · Cited by 223 · cited 5×
“…in large samples of A (cid:2) + CN adults ranges from 17.7% over an average of 3.7 years in the Mayo Clinic Study of Aging (MCSA, mean age 76) [10], 26.4% over 5 years in the Knight Alzheimer’s Disease Research Center study (Knight ADRC, mean age 72) [13], 19% over 6 years in the Australian…”
InfluentialBurnham, S. C., Bourgeat, P., Doré, V., Savage, G., Brown, B., Laws, S., Maruff, P., Salvado, O., Ames, D., Martins, R. N., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30125-9 · Cited by 207
Self-citationAge and amyloid effects on human central nervous system amyloid‐beta kinetics
Patterson, B. W., Elbert, D. L., Mawuenyega, K. G., Kasten, T., Ovod, V., Ma, S., Xiong, C., Chott, R., Yarasheski, K., Sigurdson, W., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24454 · Cited by 200
Baker, J. E., Lim, Y. Y., Pietrzak, R. H., Hassenstab, J., Snyder, P. J., Masters, C. L., & Maruff, P. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.09.002 · Cited by 200
Self-citationPetersen, R. C., Wiste, H. J., Weigand, S. D., Rocca, W. A., Roberts, R. O., Mielke, M. M., Lowe, V. J., Knopman, D. S., Pankratz, V. S., Machulda, M. M., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3098 · Cited by 196 · cited 1×
“[37].”
Subtle Cognitive Decline and Biomarker Staging in Preclinical Alzheimer’s Disease
Edmonds, E. C., 1, F. T. A. D. N. I., Delano-Wood, L., Galasko, D. R., Salmon, D. P., & Bondi, M. W. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150128 · Cited by 195 · cited 1×
“…classifications; however, the public availability of this data has meant different researchers have also utilized CDR ratings and actuarial neuropsychological approaches to define clinical status, which itself has resulted in different estimates of A (cid:2) -associated progression [15, 45, 46].”
Age, vascular health, and Alzheimer disease biomarkers in an elderly sample
Vemuri, P., Lesnick, T. G., Przybelski, S. A., Knopman, D. S., Lowe, V. J., Graff‐Radford, J., Roberts, R. O., Mielke, M. M., Machulda, M. M., Petersen, R. C., et al. (2017) · Annals of Neurology · doi:10.1002/ana.25071 · Cited by 182
Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition
Chételat, G., Villemagne, V. L., Villain, N., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Masters, C. L., & Rowe, C. C. (2012) · Neurology · doi:10.1212/wnl.0b013e318246d67a · Cited by 172
Self-citationRational Cell Culture Optimization Enhances Experimental Reproducibility in Cancer Cells
Wright Muelas, M., Ortega, F., Breitling, R., Bendtsen, C., & Westerhoff, H. V. (2018) · Scientific Reports · doi:10.1038/s41598-018-21050-4 · Cited by 160
Deeg, D. J. H. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00472-3 · Cited by 121
APOE ε4 moderates amyloid-related memory decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Pietrzak, R. H., Ames, D. J., Ellis, K. A., Harrington, K., Snyder, P. J., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.008 · Cited by 93
Self-citationNeuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
Chételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
Self-citationMultimorbidity, dementia and health care in older people:a population-based cohort study
Tonelli, M., Wiebe, N., Straus, S., Fortin, M., Guthrie, B., James, M. T., Klarenbach, S. W., Tam-Tham, H., Lewanczuk, R., Manns, B. J., et al. (2017) · CMAJ Open · doi:10.9778/cmajo.20170052 · Cited by 68 · cited 1×
“Death or withdrawal from the study due to illness were coded as competing risks because the deceased have no risk of clinical progression and those who withdraw due to illness may have higher risk [35].”
Using Robust Normative Data to Investigate the Neuropsychology of Cognitive Aging
Harrington, K., Lim, Y. Y., Ames, D. J., Hassenstab, J. J., Rainey‐Smith, S. R., Robertson, J. S., Salvado, O., Masters, C. L., & Maruff, P. T. (2016) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acw106 · Cited by 63 · cited 1×
“%) cohorts over similar time periods [15, 44], and was equal to that reported by the MCSA (17.7”
InfluentialSelf-citationCertified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning
Hassenstab, J., Chasse, R., Grabow, P., Benzinger, T. L. S., Fagan, A. M., Xiong, C., Jasielec, M., Grant, E., & Morris, J. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.014 · Cited by 57 · cited 1×
“…Study of Aging (MCSA, mean age 76) [10], 26.4% over 5 years in the Knight Alzheimer’s Disease Research Center study (Knight ADRC, mean age 72) [13], 19% over 6 years in the Australian Imaging, Biomarkers and Lifestyle study (AIBL, mean age 73) [14], to 32.2% over an average of 4 years in the…”
InfluentialSelf-citationThai, C., Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Ellis, K. A., Rainey-Smith, S. R., Martins, R. N., Masters, C. L., Rowe, C. C., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139082 · Cited by 40
Self-citationLim, Y. Y., Williamson, R., Laws, S. M., Villemagne, V. L., Bourgeat, P., Fowler, C., Rainey-Smith, S., Salvado, O., Martins, R. N., Rowe, C. C., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170072 · Cited by 40 · cited 1×
“4 carriage is associated with increased risk of both A (cid:2) + and dementia in CN older adults [19, 20], and neuropsychological studies show that A (cid:2) + APOE (cid”
Self-citationVillemagne, V. (2014) · Advances in Research · doi:10.9734/air/2014/11599 · Cited by 37 · cited 2×
“Threshold values for elevated A (cid:2) deposition vary by radiotracer, so a linear regression transformation was applied to the FBP and FLUTE SUVR to create a “PiB-like” SUVR unit called Before the Centiloid Kernel Transformation (BeCKeT) [34].”
Self-citationPorter, T., Burnham, S. C., Doré, V., Savage, G., Bourgeat, P., Begemann, K., Milicic, L., Ames, D., Bush, A. I., Maruff, P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20513-y · Cited by 37
Self-citation
Research works printed but not linked: 1
- Lim YY, 2018, JAMA Neurol, 3052, 1
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
Self-citationRetractedThe probabilistic model of Alzheimer disease: the amyloid hypothesis revised
Frisoni, G. B., Altomare, D., Thal, D. R., Ribaldi, F., van der Kant, R., Ossenkoppele, R., Blennow, K., Cummings, J., van Duijn, C., Nilsson, P. M., et al. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00533-w · Cited by 513
Lanctôt, K. L., Hahn‐Pedersen, J. H., Eichinger, C. S., Freeman, C. S., Clark, A., Tarazona, L. R. S., & Cummings, J. L. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.61 · Cited by 178
“Two studies reported data from each of Australia (27, 44), North Africa (32, 46), Brazil (54, 64), and one study reported data from Cuba (67).”
ResultKivimäki, M., Walker, K. A., Pentti, J., Nyberg, S. T., Mars, N., Vahtera, J., Suominen, S. B., Lallukka, T., Rahkonen, O., Pietiläinen, O., et al. (2021) · BMJ · doi:10.1136/bmj.n1804 · Cited by 99
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Papp, K. V., Buckley, R., Mormino, E., Maruff, P., Villemagne, V. L., Masters, C. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., Amariglio, R. E., et al. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.074 · Cited by 86
Self-citation
Metadata
- Authors
- Dang, C., Harrington, K. D., Lim, Y. Y., Ames, D., Hassenstab, J., Laws, S. M., Yassi, N., Hickey, M., Rainey-Smith, S., Robertson, J., Sohrabi, H. R., Salvado, O., Weinborn, M., Villemagne, V. L., Rowe, C. C., Masters, C. L., Maruff, P., & for the AIBL Research Group
- Affiliations
- The University of Melbourne (AU)
- Washington University in St. Louis (US)
- Edith Cowan University (AU)
- The Royal Melbourne Hospital (AU)
- Centre of Excellence for Alzheimer’s Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia
- Commonwealth Scientific and Industrial Research Organisation (AU)
- Corresponding author
- Dang, Christa
- ORCID
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2018-08-22
- Volume
- 65
- Issue
- 4
- Pages
- 1313-1325
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2888422974
- Cited by
- 31
- References
- 45
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 5 · 2021: 6 · 2020: 5 · 2019: 2
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Alzheimer s Disease (publishedVersion)
- PubMed (publishedVersion)
- Murdoch University Research Portal (submittedVersion)
- Edith Cowan University Research Online (Edith Cowan University) (submittedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- cerebral amyloid-beta, preclinical Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Aging, Cerebral Cortex, Dementia, Female, Humans, Longitudinal Studies, Male, Middle Aged, Survival Analysis, Amyloid beta-Peptides, Disease Progression, Statistics, Nonparametric, Positron-Emission Tomography, Apolipoprotein E4, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.